Spnib 50 mg Tablet is an anti-cancer medicine used in the treatment of Leukemia. Leukemia, also known as blood cancer, is a cancer of blood cells or blood-forming tissues. It causes excessive production of immature white blood cells by the bone marrow and reduces the body’s ability to fight infections. There are different types of blood cancers. Spnib 50 mg Tablet is used in the treatment of chronic myelogenous leukemia (CML) in patients with chronic, accelerated, or blast phase Ph+ (Philadelphia chromosome-positive) who are resistant or intolerant to prior therapy, in patients with newly diagnosed chronic Ph+ chronic myelogenous leukemia (CML). This medicine is also used in the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Spnib 50 mg Tablet contains Dasatinib, which belongs to the class of kinase inhibitors. It works by inhibiting the action of abnormal proteins that cause the multiplication of cancerous cells. This helps stop the abnormal growth of cancer cells and thus reduce the further spread to other parts of the body.

Spnib 50 mg Tablet may cause certain side effects, such as skin rash, fatigue, headache, musculoskeletal pain, decreased platelet count, nausea, vomiting, diarrhea, abdominal pain, dizziness, GI bleeding, muscle inflammation, myalgia, and difficulty breathing. These side effects do not require medical attention and gradually resolve over time. However, if the side effects persist or worsen, please consult your doctor. Spnib 50 mg Tablet should be taken as advised by your doctor. Do not take more than the recommended dose of medicine. Your doctor will decide the dose of Spnib 50 mg Tablet based on the severity of your condition.

Spnib 50 mg Tablet should be avoided if you are allergic to it or any other components present in it. Before taking Spnib 50 mg Tablet , caution should be exercised if you have/had liver/kidney disease, gastrointestinal disorders, cardiac problems, and myelosuppression as may cause serious side effects or worsen such conditions. This medicine is known to cause embryo-fetal toxicity. Hence, inform your doctor if you are pregnant or are planning to become pregnant before starting the treatment with Spnib 50 mg Tablet . Breastfeeding should be discontinued in nursing mothers during the treatment.

Spnib 50 mg Tablet contains Dasatinib, which belongs to the class of kinase inhibitors. It works by inhibiting the action of abnormal proteins (BCR-ABL tyrosine kinase) that cause the multiplication of cancerous cells. This helps stop the abnormal growth of cancer cells and thus reduce the further spread to other parts of the body. Spnib 50 mg Tablet is used in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.

Spnib 50 mg Tablet should be avoided if you are allergic to it or any other components present in it. Let your doctor know about your complete medical history, including current medication, to rule out any side effects/interactions. Before taking, inform your doctor if you have liver/kidney disease, diabetes, cardiac problems, increased blood pressure, or gastrointestinal disorders, as the use of Spnib 50 mg Tablet in these patients may cause serious side effects. Spnib 50 mg Tablet may cause myelosuppression, fluid retention, gastrointestinal haemorrhage, QT prolongation, congestive heart failure, Left ventricular dysfunction and Myocardial infarction. This medicine is known to cause embryo-fetal toxicity. Hence, inform your doctor if you are pregnant or are planning to become pregnant before starting the treatment. Breastfeeding should be discontinued in nursing mothers during the treatment. Spnib 50 mg Tablet is given in children above one year of age only if prescribed by the doctor. Avoid alcohol consumption and smoking, as it can lead to serious adverse effects.